Oncolytic viruses: The power of directed evolution

Advances in Virology

Volumn 2012, Issue , 2012, Pages

  Bauzon, Maxine ^a   Hermiston, Terry W ^a  

^a BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855259830     PISSN: 16878639     EISSN: 16878647     Source Type: Journal    
DOI: 10.1155/2012/586389     Document Type: Review

References (38)

1. Araujo R. P., Liotta L. A., Petricoin E. F., Proteins, drug targets and the mechanisms they control: the simple truth about complex networks. Nature Reviews Drug Discovery 2007 6 11 871 880 2-s2.0-35748935235 10.1038/nrd2381 (Pubitemid 350042395)
2. Hann C. L., Brahmer J. R., Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when? Current Treatment Options in Oncology 2007 8 1 28 37 2-s2.0-36049010648 10.1007/s11864-007-0024-2
3. Rosa D. D., Ismael G., Lago L. D., Awada A., Molecular-targeted therapies: lessons from years of clinical development. Cancer Treatment Reviews 2008 34 1 61 80 2-s2.0-38649109498 10.1016/j.ctrv.2007.07.019 (Pubitemid 351168606)
4. Breitbach C. J., Reid T., Burke J., Bell J. C., Kirn D. H., Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval. Cytokine and Growth Factor Reviews 2010 21 2-3 85 89 2-s2.0-77953543075 10.1016/j.cytogfr.2010.02.001
5. Parato K. A., Senger D., Forsyth P. A. J., Bell J. C., Recent progress in the battle between oncolytic viruses and tumours. Nature Reviews Cancer 2005 5 12 965 976 2-s2.0-28844444483 10.1038/nrc1750 (Pubitemid 41766784)
6. Reid T., Warren R., Kirn D., Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Therapy 2002 9 12 979 986 2-s2.0-0036904741 10.1038/sj.cgt.7700539 (Pubitemid 35462561)
7. Yu D. C., Working P., Ando D., Selectively replicating oncolytic adenoviruses as cancer therapeutics. Current Opinion in Molecular Therapeutics 2002 4 5 435 443 2-s2.0-0036820166 (Pubitemid 36305035)
8. Zwiebel J. A., Cancer gene and oncolytic virus therapy. Seminars in Oncology 2001 28 4 336 343 2-s2.0-0034889728 (Pubitemid 32762079)
9. Crompton A. M., Kirn D. H., From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Current Cancer Drug Targets 2007 7 2 133 139 2-s2.0-33847370331 10.2174/156800907780058862 (Pubitemid 46348627)
10. Kuhn I., Harden P., Bauzon M., Chartier C., Nye J., Thorne S., Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS ONE 2008 3 6 e2409 10.1371/journal.pone.0002409
11. Yan W., Kitzes G., Dormishian F., Hawkins L., Sampson-Johannes A., Watanabe J., Holt J., Lee V., Dubensky T., Fattaey A., Hermiston T., Balmain A., Shen Y., Developing novel oncolytic adenoviruses through bioselection. Journal of Virology 2003 77 4 2640 2650 2-s2.0-0037323323 10.1128/JVI.77.4.2640-2650. 2003 (Pubitemid 36222789)
12. Gros A., Martínez-Quintanilla J., Puig C., Guedan S., Molleví D. G., Alemany R., Cascallo M., Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency. Cancer Research 2008 68 21 8928 8937 2-s2.0-55349119141 10.1158/0008-5472.CAN-08-1145
13. Kwon I., Schaffer D. V., Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer. Pharmaceutical Research 2008 25 3 489 499 2-s2.0-40549119871 10.1007/s11095-007-9431-0
14. Yang L., Li J., Xiao X., Directed evolution of adeno-associated virus (AAV) as vector for muscle gene therapy. Methods in Molecular Biology 2011 709 127 139
15. Kuhn I., Larsen B., Gross C., Hermiston T., High-performance liquid chromatography method for rapid assessment of viral particle number in crude adenoviral lysates of mixed serotype. Gene Therapy 2007 14 2 180 184 2-s2.0-33846013953 10.1038/sj.gt.3302851 (Pubitemid 46043823)
16. Garber K., China approves world's first oncolytic virus therapy for cancer treatment. Journal of the National Cancer Institute 2006 98 5 298 300 2-s2.0-33644852717
17. Gaggar A., Shayakhmetov D. M., Lieber A., CD46 is a cellular receptor for group B adenoviruses. Nature Medicine 2003 9 11 1408 1412 2-s2.0-0345708273 10.1038/nm952 (Pubitemid 37466191)
18. Marttila M., Persson D., Gustafsson D., Liszewski M. K., Atkinson J. P., Wadell G., Arnberg N., CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7. Journal of Virology 2005 79 22 14429 14436 2-s2.0-27644540098 10.1128/JVI.79.22.14429-14436.2005 (Pubitemid 41552740)
19. Anderson B. D., Nakamura T., Russell S. J., Peng K. W., High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Research 2004 64 14 4919 4926 2-s2.0-3142745262 10.1158/0008-5472.CAN-04-0884 (Pubitemid 38924538)
20. Murray K. P., Mathure S., Kaul R., Khan S., Carson L. F., Twiggs L. B., Martens M. G., Kaul A., Expression of complement regulatory proteins-CD 35, CD 46, CD 55, and CD 59-in benign and malignant endometrial tissue. Gynecologic Oncology 2000 76 2 176 182 2-s2.0-0033974021 10.1006/gyno.1999.5614 (Pubitemid 30067192)
21. Hermiston T., Fighting fire with fire: attacking the complexity of human tumors with armed therapeutic viruses. Current Opinion in Molecular Therapeutics 2002 4 4 334 342 2-s2.0-0036705516 (Pubitemid 36305024)
22. Hermiston T. W., Kuhn I., Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Therapy 2002 9 12 1022 1035 2-s2.0-0036903141 10.1038/sj.cgt.7700542 (Pubitemid 35462564)
23. Thorne S. H., Hermiston T., Kirn D., Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects. Seminars in Oncology 2005 32 6 537 548 2-s2.0-28844496639 10.1053/j.seminoncol.2005.09.007 (Pubitemid 41772681)
24. Hawkins L. K., Hermiston T., Gene delivery from the E3 region of replicating human adenovirus: evaluation of the E3B region. Gene Therapy 2001 8 15 1142 1148 2-s2.0-0034887983 10.1038/sj.gt.3301509 (Pubitemid 32776387)
25. Hawkins L. K., Hermiston T. W., Gene delivery from the E3 region of replicating human adenovirus: evaluation of the ADP region. Gene Therapy 2001 8 15 1132 1141 2-s2.0-0034893340 10.1038/sj.gt.3301508 (Pubitemid 32776386)
26. Hawkins L. K., Johnson L., Bauzon M., Nye J. A., Castro D., Kitzes G. A., Young M. D., Holt J. K., Trown P., Hermiston T. W., Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7-K/gp19 K region. Gene Therapy 2001 8 15 1123 1131 2-s2.0-17944371743 10.1038/sj.gt.3301507 (Pubitemid 32776385)
27. Bauzon M., Castro D., Karr M., Hawkins L. K., Hermiston T. W., Multigene expression from a replicating adenovirus using native viral promoters. Molecular Therapy 2003 7 4 526 534 2-s2.0-0038027290 10.1016/S1525-0016(03)00023-6 (Pubitemid 36553422)
28. Ding D., Russell S. J., Morris J. C. III, In vivo imaging and tumor therapy with the sodium iodide symporter. Journal of Cellular Biochemistry 2003 90 6 1079 1086 2-s2.0-0344442900 10.1002/jcb.10714 (Pubitemid 37485046)
29. Kretschmer P. J., Jin F., Chartier C., Hermiston T. W., Development of a transposon-based approach for identifying novel transgene insertion sites within the replicating adenovirus. Molecular Therapy 2005 12 1 118 127 2-s2.0-20844454803 10.1016/j.ymthe.2005.03.019 (Pubitemid 40862363)
30. Jin F., Kretschmer P. J., Hermiston T. W., Identification of novel insertion sites in the Ad5 genome that utilize the Ad splicing machinery for therapeutic gene expression. Molecular Therapy 2005 12 6 1052 1063 2-s2.0-28444474772 10.1016/j.ymthe.2005.07.696 (Pubitemid 41723039)
31. Bauzon M., Jin F., Kretschmer P., Hermiston T., In vitro analysis of cidofovir and genetically engineered TK expression as potential approaches for the intervention of ColoAd1-based treatment of cancer. Gene Therapy 2009 16 9 1169 1174 2-s2.0-70249099553 10.1038/gt.2009.69
32. Lenaerts L., Naesens L., Antiviral therapy for adenovirus infections. Antiviral Research 2006 71 2-3 172 180 2-s2.0-33747085476 10.1016/j.antiviral. 2006.04.007 (Pubitemid 44223761)
33. Ljungman P., Viral infections: current diagnosis and treatment. Hematology Journal 2004 5 3 S63 S68 2-s2.0-4043133065 10.1038/sj.thj.6200425 (Pubitemid 39077277)
34. Neofytos D., Ojha A., Mookerjee B., Wagner J., Filicko J., Ferber A., Dessain S., Grosso D., Brunner J., Flomenberg N., Flomenberg P., Treatment of adenovirus disease in stem cell transplant recipients with cidofovir. Biology of Blood and Marrow Transplantation 2007 13 1 74 81 2-s2.0-33846015837 10.1016/j.bbmt.2006.08.040 (Pubitemid 46044089)
35. Baba M., Mori S., Shigeta S., De Clercq E., Selective inhibitory effect of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 2'-nor-cyclic GMP on adenovirus replication in vitro. Antimicrobial Agents and Chemotherapy 1987 31 2 337 339 2-s2.0-0023143963 (Pubitemid 17011267)
36. Morfin F., Dupuis-Girod S., Mundweiler S., Falcon D., Carrington D., Sedlacek P., Bierings M., Cetkovsky P., Kroes A. C. M., Van Tol M. J. D., Thouvenot D., In vitro susceptibility of adenovirus to antiviral drugs is species-dependent. Antiviral Therapy 2005 10 2 225 229 2-s2.0-18144367651 (Pubitemid 41151028)
37. Wildner O., Hoffmann D., Jogler C., Überla K., Comparison of HSV-1 thymidine kinase-dependent and -independent inhibition of replication-competent adenoviral vectors by a panel of drugs. Cancer Gene Therapy 2003 10 10 791 802 2-s2.0-0141885152 10.1038/sj.cgt.7700638 (Pubitemid 37243800)
38. Bhaumik S., Advances in imaging gene-directed enzyme prodrug therapy. Current Pharmaceutical Biotechnology 2011 12 4 497 507